Fundraising Fox
/Companies
Sign in

Carisma Therapeutics

Philadelphia, US · Founded 2017 · Delaware corporation · 13 known investors

Find your way into Carisma Therapeutics

435 people in our graph share verified history with the Carisma Therapeutics team — schools, employers, funds. One of them is your warm intro.

Emanuel Ortizunlockedknows Steven Kelly · together at Carisma Therapeutics (overlapped)
×3knows the team · via Carisma Therapeutics
×6knows the team · via Amgen
×2knows the team · via University of Oregon

CAR-Macrophage cellular therapeutics with initial oncology focus (NASDAQ: CARM).

Biotech

Founders & leadership

SKSteven Kelly
Steven KellyPresident and Chief Executive Officer2018–2025Steven Kelly has three decades of experience in biopharmaceutical industry roles spanning both established and emerging companies, with background in company formation, fundraising, and business development. He serves as Executive Officer and Director at Carisma Therapeutics, a developer of CAR-Macrophage cellular therapeutics.

Board

MC
Margarita ChavezBoard Member2017–2023Managing Director at AbbVie
EN
Eran NadavBoard director
AS
Althea StillmanBoard director
JG
Jacob GunterbergBoard director
RHRegina Hodits
Regina HoditsBoard directorManaging Director at Angelini Ventures

Investors · 13

Aju IB Invesment Corporationlisted by Aju IB Invesment CorporationSeoul
Anzu Partnerslisted by Anzu PartnersBillerica

How we know: Anzu Partners's portfolio page · Not right? Tell us

Grazia Equity GmbHlisted by Grazia Equity GmbHStuttgart · $540K – $2.7M

How we know: prnewswire.com · Not right? Tell us

HealthCaplisted by HealthCapStockholm

How we know: HealthCap's portfolio page · prnewswire.com · Not right? Tell us

MRL Ventures Fundlisted by MRL Ventures FundCambridge · $25M

How we know: MRL Ventures Fund's portfolio page · prnewswire.com · Not right? Tell us

Solasta Ventureslisted by Solasta VenturesBoston
AbbViereportedCambridge · $300K – $3M

How we know: a partner's Signal profile · Not right? Tell us

M VenturesreportedLos Angeles · $10.8M

How we know: a partner's Signal profile · Not right? Tell us

SymBiosisinferredBentonvillevia Chidozie Ugwumba · board

How we know: board seat on SEC Form D · Not right? Tell us

Also in the syndicate · 3

AbbVie VenturesleadIP GroupPenn Medicine

Reported raises · per SEC filings

Form D private placements

$95M disclosed across 3 rounds · 2017–2020

▶$38.3MraisedJan 2021 · 13 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Briggs MorrisonDirector
  • Jacob GunterbergDirector
  • Regina HoditsDirector
  • Michael HeffernanDirector
  • Chidozie UgwumbaDirector
  • Margarita ChavezDirector
  • Steven KellyExecutive Officer, Director
Offering amount
$70.4M
Amount sold
$38.3M
First sale
Dec 2020
Incorporated
Corporation, Delaware, 2017
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$52.9MraisedJul 2020 · 11 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Steven KellyExecutive Officer, Director
  • Margarita ChavezDirector
  • Eran NadavDirector
  • Althea StillmanDirector
  • Jacob GunterbergDirector
  • Regina HoditsDirector
Offering amount
$52.9M
Amount sold
$52.9M
First sale
Jun 2018
Incorporated
Corporation, Delaware, 2017
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$3.9MraisedApr 2018 · 7 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Margarita ChavezDirector
  • Steven KellyExecutive Officer, Director
  • Bruce PeacockDirector
  • Michael PoiselDirector
Offering amount
$3.9M
Amount sold
$3.9M
First sale
May 2017
Incorporated
Corporation, Delaware, 2017
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Founder mafia

3 people who came through Carisma Therapeutics went on to found or lead other companies.

Ross LeimbergBoard ObserverFounded Cantai TherapeuticsSandy ZweifachChairman of the BoardFounded ImidomicsSteven KellyExecutive Officer, DirectorFounded Pinteon Therapeutics

Competitors · 3

by search overlap
Simply Wall St9 shared keywordsSimply Wall St is an investment platform that provides financial data visualization and analysis tools for individual investors. The platform serves long-term investors globally by simplifying complex market information into visual and narrative formats to make stock investing more accessible.
Robinhood9 shared keywordsRobinhood is a financial trading platform that enables users to manage portfolios across stocks, ETFs, cryptocurrencies, options, futures, and prediction markets. The platform serves retail investors with low barriers to entry, offering portfolio management services and market insights.
StockTwits8 shared keywordsStocktwits operates an online community platform where investors and traders share ideas, analysis, and trade discussions organized around stock tickers. The page presented is its community guidelines rather than a product description.

Companies competing with Carisma Therapeutics for the same Google search keywords, organic and paid, via search-intersection analysis.

In the news

Carisma Therapeutics Announces a $53 Million Series A Financing to Develop Novel CAR Macrophage Cellular Immunotherapyprnewswire.com · Jun 2018

Frequently asked questions

What does Carisma Therapeutics do?
CAR-Macrophage cellular therapeutics with initial oncology focus (NASDAQ: CARM).
Who are Carisma Therapeutics's investors?
Carisma Therapeutics's investors include Agent Capital, Aju IB Invesment Corporation, Anzu Partners, Grazia Equity GmbH, HealthCap, MRL Ventures Fund, Solasta Ventures, AbbVie and 2 more.
How much funding has Carisma Therapeutics raised?
Carisma Therapeutics has disclosed $95M raised across 3 rounds.
Where is Carisma Therapeutics headquartered?
Carisma Therapeutics is headquartered in Philadelphia, US.